Patients Make New Medicines Possible

Pieris Pharmaceuticals is currently enrolling patients in respiratory and immuno-oncology clinical trials. New treatments are made possible by volunteers who participate in clinical trials and we highly encourage and welcome your participation.

Respiratory Trials

A Phase 2 Dose-escalating Trial of PRS-060 for Asthma

Our Phase 2 study is designed to investigate the safety, tolerability, pharmacokinetics, and efficacy of multiple doses of PRS-060, a promising drug candidate being developed to treat asthma. PRS-060 will be administered by oral inhalation to subjects with moderate asthma.

About PRS-060 Dose-escalating Clinical Trial

Immuno-Oncology Trials

A Phase 1 Study of PRS-344/S095012 to Treat Advanced Solid Tumors

This global, open-label phase 1/2 dose escalation study is evaluating the safety, tolerability, potential optimal dosage, and potential anti-tumor activity of PRS-344/S095012 in patients with advanced solid tumors whose cancer progressed on standard-of-care treatment.